BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28654711)

  • 1. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
    Eichenfield LF; Stein Gold LF
    Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
    Woo TE; Kuzel P
    Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atopic dermatitis: emerging therapies.
    Simpson E; Udkoff J; Borok J; Tom W; Beck L; Eichenfield LF
    Semin Cutan Med Surg; 2017 Sep; 36(3):124-130. PubMed ID: 28895959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atopic Dermatitis: New Developments.
    Kusari A; Han AM; Schairer D; Eichenfield LF
    Dermatol Clin; 2019 Jan; 37(1):11-20. PubMed ID: 30466683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
    Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
    J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging topical therapies for atopic dermatitis.
    Udkoff J; Waldman A; Ahluwalia J; Borok J; Eichenfield LF
    Clin Dermatol; 2017; 35(4):375-382. PubMed ID: 28709568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What's New in Atopic Dermatitis.
    Renert-Yuval Y; Guttman-Yassky E
    Dermatol Clin; 2019 Apr; 37(2):205-213. PubMed ID: 30850043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
    Purohit V; Riley S; Tan H; Ports WC
    J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
    Riahi A; Lam JM
    Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crisaborole: A new and effective nonsteroidal topical drug for atopic dermatitis.
    Kailas A
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28834023
    [No Abstract]   [Full Text] [Related]  

  • 11. Topical Crisaborole in the Treatment of Atopic Hand Dermatitis: A Retrospective Chart Review.
    Kahn JS; Grossman-Kranseler JS; Zancanaro P; Griffiths D; Dumont N; Rosmarin D
    Dermatitis; 2021 Nov-Dec 01; 32(6):e141-e143. PubMed ID: 34570730
    [No Abstract]   [Full Text] [Related]  

  • 12. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
    Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
    Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current and upcoming treatments of adult atopic dermatitis].
    Lacour JP
    Ann Dermatol Venereol; 2017 Dec; 144 Suppl 5():VS29-VS37. PubMed ID: 29433635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF; Gebauer K; Spelman L; Zane LT
    J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
    Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
    J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crisaborole 2% Ointment (Eucrisa
    Gupta AK; Versteeg SG; Abramovits W; Vincent KD
    Skinmed; 2017; 15(5):377-380. PubMed ID: 29139367
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating crisaborole as a treatment option for atopic dermatitis.
    Ramachandran V; Cline A; Feldman SR; Strowd LC
    Expert Opin Pharmacother; 2019 Jun; 20(9):1057-1063. PubMed ID: 31002539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the New and Emerging Treatments for Atopic Dermatitis.
    Eichenfield LF; Friedlander SF; Simpson EL; Irvine AD
    Semin Cutan Med Surg; 2016 Jun; 35(5 Suppl):S92-6. PubMed ID: 27525671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.